TNYA Form 4: CEO tax-related sale, 299,666 shares owned

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. reported a routine insider transaction by its Chief Executive Officer, who is also a director. On 11/17/2025, the reporting person sold 3,126 shares of Tenaya Therapeutics common stock at a price of $1.33 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units originally awarded on February 6, 2025.

After this tax-related sale, the reporting person beneficially owned a total of 299,666 shares of Tenaya Therapeutics common stock. This total includes 211,275 shares that will be issued upon the future vesting of restricted stock units. The filing indicates that the ownership is held directly by the reporting person.

Insider Trade Summary

Net Seller: 3,126 shares ($4,158)

Net Sell 1 txn

Insider Ali Faraz

Role Chief Executive Officer

Sold 3,126 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,126	$1.33	$4K

Holdings After Transaction: Common Stock — 299,666 shares (Direct)

Footnotes (1)

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. Includes 211,275 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Faraz

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		3,126	D	$1.33	299,666(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

2. Includes 211,275 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tenaya Therapeutics (TNYA) report in this Form 4?

The filing reports that on 11/17/2025 the Chief Executive Officer and director of Tenaya Therapeutics, Inc. sold 3,126 shares of common stock at $1.33 per share.

Why did the Tenaya Therapeutics (TNYA) executive sell 3,126 shares?

The filing states that the 3,126 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units awarded on February 6, 2025.

How many Tenaya Therapeutics (TNYA) shares does the reporting person own after the transaction?

Following the reported sale, the reporting person beneficially owned 299,666 shares of Tenaya Therapeutics common stock.

How many Tenaya Therapeutics (TNYA) shares are tied to unvested restricted stock units?

The total beneficial ownership of 299,666 shares includes 211,275 shares that will be issued upon the vesting of restricted stock units.

What roles does the reporting person hold at Tenaya Therapeutics (TNYA)?

The individual is identified as both a director and an officer, serving as the Chief Executive Officer of Tenaya Therapeutics, Inc.

Is the ownership reported in this Tenaya Therapeutics (TNYA) Form 4 direct or indirect?

The filing shows that the 299,666 shares of beneficially owned common stock are held with direct ownership.